Its a new kind of risk, the Price-Safety Trap
During its earnings call last week, Lilly noted that its shipments of Zepbound were slightly lower than original projections, but an analyst note from investment firm Jefferies commented that this isnt a concern because it doesn't seem to be driven by lack of demand. But while Lilly and Novo Nordisk have built up a good headstart when it comes to the obesity space, competition is on the horizon
By pairing semaglutide with Regenerons anti-myostatin, trevogrumab, patients could lose similar amounts of body weight, but the weight lost would be 76-80% fat vs
Multiple strategies can reduce these costs significantly
MIC components are known for their fat-burning and liver-supporting properties, which, when paired with Semaglutide's appetite control, create a synergistic effect